149 related articles for article (PubMed ID: 21507934)
1. Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.
Díez-Dacal B; Gayarre J; Gharbi S; Timms JF; Coderch C; Gago F; Pérez-Sala D
Cancer Res; 2011 Jun; 71(12):4161-71. PubMed ID: 21507934
[TBL] [Abstract][Full Text] [Related]
2. Study of protein targets for covalent modification by the antitumoral and anti-inflammatory prostaglandin PGA1: focus on vimentin.
Gharbi S; Garzón B; Gayarre J; Timms J; Pérez-Sala D
J Mass Spectrom; 2007 Nov; 42(11):1474-84. PubMed ID: 17960581
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
4. Differential selectivity of protein modification by the cyclopentenone prostaglandins PGA1 and 15-deoxy-Delta12,14-PGJ2: role of glutathione.
Gayarre J; Stamatakis K; Renedo M; Pérez-Sala D
FEBS Lett; 2005 Oct; 579(25):5803-8. PubMed ID: 16223487
[TBL] [Abstract][Full Text] [Related]
5. A biotinylated analog of the anti-proliferative prostaglandin A1 allows assessment of PPAR-independent effects and identification of novel cellular targets for covalent modification.
Garzón B; Gayarre J; Gharbi S; Díez-Dacal B; Sánchez-Gómez FJ; Timms JF; Pérez-Sala D
Chem Biol Interact; 2010 Jan; 183(1):212-21. PubMed ID: 19800325
[TBL] [Abstract][Full Text] [Related]
6. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
7. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
8. Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
Díez-Dacal B; Sánchez-Gómez FJ; Sánchez-Murcia PA; Milackova I; Zimmerman T; Ballekova J; García-Martín E; Agúndez JA; Gharbi S; Gago F; Stefek M; Pérez-Sala D
Mol Pharmacol; 2016 Jan; 89(1):42-52. PubMed ID: 26487510
[TBL] [Abstract][Full Text] [Related]
9. Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Joshi A; Rajput S; Wang C; Ma J; Cao D
Biol Chem; 2010 Dec; 391(12):1371-8. PubMed ID: 21087085
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
11. A-class prostaglandins: early findings and new perspectives for overcoming tumor chemoresistance.
Díez-Dacal B; Pérez-Sala D
Cancer Lett; 2012 Jul; 320(2):150-7. PubMed ID: 22407242
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
[TBL] [Abstract][Full Text] [Related]
14. Direct evidence for the covalent modification of glutathione-S-transferase P1-1 by electrophilic prostaglandins: implications for enzyme inactivation and cell survival.
Sánchez-Gómez FJ; Gayarre J; Avellano MI; Pérez-Sala D
Arch Biochem Biophys; 2007 Jan; 457(2):150-9. PubMed ID: 17169324
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
16. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.
Barski OA; Gabbay KH; Bohren KM
Biochemistry; 1996 Nov; 35(45):14276-80. PubMed ID: 8916913
[TBL] [Abstract][Full Text] [Related]
17. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Endo S; Matsunaga T; Kuwata K; Zhao HT; El-Kabbani O; Kitade Y; Hara A
Bioorg Med Chem; 2010 Apr; 18(7):2485-90. PubMed ID: 20304656
[TBL] [Abstract][Full Text] [Related]
18. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids.
Hara A; Endo S; Matsunaga T; Soda M; El-Kabbani O; Yashiro K
Arch Biochem Biophys; 2016 Nov; 609():69-76. PubMed ID: 27665999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
